Author Index Volume 28 (2016)

The issue number is given in front of the page numbers

Abi-Jaoude, E., see Le Noury, J. (3) 143–161
Afifi, S., see Peymani, P. (1) 25–31
Amsterdam, J.D., see Jureidini, J.N. (1) 33–43
Awodele, O., A. Ibrahim and P. Orhii, Patterns of adverse drug reaction signals in NAFDAC Pharmacovigilance activities from September to November, 2014 (1) 13–23
Baldo, V., see Buja, A. (3) 163–170
Bassi, P., see Ogunleye, O.O. (2) 77–91
Cacco, R.M., see Buja, A. (3) 163–170
Cohen, D., see Hughes, S. (2) 101–114
Cruz, R.S., see dos Reis, C. (1) 45–60
Danborg, P.B., see Simonsen, A.L. (1) 1–12
Dario, C., see Buja, A. (3) 163–170
De Battisti, E., see Buja, A. (3) 163–170
Dias, J.J., see Mehta, S. (2) 65–75
dos Reis, C., R. Teixo, F. Mendes and R.S. Cruz, Biosimilar medicines – Review (1) 45–60
Ekoja, M., see Ogunleye, O.O. (2) 77–91
El-Enein, N.Y.A., see Zaghloul, A.A. (2) 93–99
Enwere, O., see Ogunleye, O.O. (2) 77–91
Estep, J.D., see Alvarez, P.A. (4) 181–188
Falade, C., see Ogunleye, O.O. (2) 77–91
Ganduglia, C., see Alvarez, P.A. (4) 181–188
Gotzsche, P.C., see Simonsen, A.L. (1) 1–12
Graviss, E.A., see Alvarez, P.A. (4) 181–188
Grech, V., Response to a Letter to the Editor (3) 175–176
Healy, D., J. Le Noury and D. Mangin, Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: A systematic review of epidemiological and physiological evidence (3) 125–141
Healy, D., see Le Noury, J. (3) 143–161
Heydari, S.T., see Peymani, P.  
Hughes, S., D. Cohen and R. Johnson, Adverse event assessment methods in published trials of psychotropic drugs: Poor reporting and neglect of emerging safety concerns  
Ibrahim, A., see Awodele, O.  
Isah, A., see Ogunleye, O.O.  
Jargin, S.V., Concerning a Letter to the Editor  
Johnson, R., see Hughes, S.  
Jørgensen, K.J., see Ziganshina, L.E.  
Jureidini, J., see Le Noury, J.  
Jureidini, J.N., J.D. Amsterdam and L.B. McHenry, The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance  
Kapp, M.B., Defensive medicine: No wonder policymakers are confused  
Kapp, M.B., Front office staff as medical educators, risk creators, and risk managers  
Kilani, J., see Ogunleye, O.O.  
Kolfschoten, J., see Rolfes, L.  
Kooijman, M., see Rolfes, L.  
Lankarani, K.B., see Peymani, P.  
Le Noury, J., see Healy, D.  
Maharlouei, N., see Peymani, P.  
Mangin, D., see Healy, D.  
McHenry, L.B., see Jureidini, J.N.  
Mehta, S., H.P. Singh and J.J. Dias, Effect of patient safety incident review and reflection in an extended morbidity and mortality meeting  
Mendes, F., see dos Reis, C.  
Namazi, S., see Peymani, P.  
Nardo, J.M., see Le Noury, J.  
Nguyen, D.T., see Alvarez, P.A.  
Nouraei, H., see Peymani, P.  
Obiako, R., see Ogunleye, O.O.  
Obodo, J., see Ogunleye, O.O.  
Odesanya, R., see Ogunleye, O.O.  
Ogundele, S.O., see Ogunleye, O.O.  
Olayemi, S., see Ogunleye, O.O.  (2) 77–91
Oreagba, I.A., see Ogunleye, O.O.  (2) 77–91
Orhi, P., see Awodele, O.  (1) 13–23
Ottoliti, K., see Buja, A.  (3) 163–170

Putney, D., see Alvarez, P.A.  (4) 181–188
Rahman, S.A., see Zaghloul, A.A.  (2) 93–99
Raven, M., see Le Noury, J.  (3) 143–161
Rodriguez-Monguio, R., see Kwon, C.S.  (4) 197–211
Rolfes, L., J. Kolfshoten, F. van Hunsel, M. Kooijman and E. van Puijenbroek, Actions in response to drug safety signals arising from a spontaneous reporting system: Retrospective study in The Netherlands  (2) 115–123
Sadeghi, E., see Peymani, P.  (1) 25–31
Saieva, A.M., see Buja, A.  (3) 163–170
Scherb, H., Comment on a Letter to the Editor  (3) 177–180
Schutt, R., see Alvarez, P.A.  (4) 181–188
Seoane-Vazquez, E., see Kwon, C.S.  (4) 197–211
Shirazi, M.K., see Peymani, P.  (1) 25–31
Simonsen, A.L., P.B. Danborg and P.C. Gøtzsche, Persistent sexual dysfunction after early exposure to SSRIs: Systematic review of animal studies  (1) 1–12
Singh, H.P., see Mehta, S.  (2) 65–75
Tabrizi, R., see Peymani, P.  (1) 25–31
Teixo, R., see dos Reis, C.  (1) 45–60
Tufanaru, C., see Le Noury, J.  (3) 143–161
van Hunsel, F., see Rolfes, L.  (2) 115–123
van Puijenbroek, E., see Rolfes, L.  (2) 115–123
Vinelli, A., see Buja, A.  (3) 163–170
Yaxley, J., Common analgesic agents and their role in analgesic nephropathy: A commentary of the evidence  (4) 189–196

Zaghloul, A.A., S.A. Rahman and N.Y.A. El-Enein, Obligation towards medical errors disclosure at a tertiary care hospital in Dubai, UAE  (2) 93–99